Vir Biotechnology, Inc. (VIR) Earnings History
Net Loss9 years of earnings data (2017–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Vir Biotechnology, Inc. (VIR) Earnings Overview
As of June 29, 2026, Vir Biotechnology, Inc. (VIR) reported trailing twelve-month net income of -$443M, reflecting +17.5% year-over-year growth. The company earned $-3.00 per diluted share over the past four quarters, with a net profit margin of -638.9%.
Looking at the long-term picture, VIR's historical earnings data spans multiple years. The company achieved its highest annual net income of $529M in fiscal 2021.
Vir Biotechnology, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including REGN ($4.42B net income, 31.4% margin), MNKD (-$24M net income, 1.7% margin), AGEN ($65M net income, 0.1% margin), VIR has room to improve margins relative to the peer group. Compare VIR vs REGN →
VIR Earnings vs Peers
Earnings metrics vs comparable public companies
VIR Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$438M | +16.1% | -$468M | $-3.16 | -638.9% | -682.7% |
| 2024 | -$522M | +15.1% | -$587M | $-3.83 | -703.4% | -791.3% |
| 2023 | -$615M | -219.2% | -$684M | $-4.59 | -713.7% | -794.0% |
| 2022 | $516M | -2.4% | $833M | $3.83 | 31.9% | 51.6% |
| 2021 | $529M | +277.0% | $421M | $3.96 | 48.3% | 38.4% |
| 2020 | -$299M | -71.0% | -$297M | $-2.51 | -444.1% | -441.6% |
| 2019 | -$175M | -50.7% | -$178M | $-1.62 | -24568.6% | -25032.2% |
| 2018 | -$116M | -65.9% | -$119M | $-1.20 | -13350.7% | -13674.2% |
| 2017 | -$70M | - | -$81M | $-10.02 | -46880.5% | -54696.0% |
Download Data
Export VIR earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
VIR — Frequently Asked Questions
Quick answers to the most common questions about buying VIR stock.
What is VIR earnings per share (EPS)?
VIR trailing twelve-month (TTM) diluted EPS is $-3.00, reflecting +17.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.
What is Vir Biotechnology, Inc.'s net income?
Vir Biotechnology, Inc. (VIR) trailing twelve-month net income is $-443M as of 2025. Earnings grew +17.5% year-over-year.
Is VIR profitable?
VIR is not currently profitable on a TTM basis, reporting a net loss of $-443M. Net margin is -638.9%. Investors should monitor for a return to profitability.
What is VIR's earnings growth rate?
VIR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.
What are VIR's profit margins?
Vir Biotechnology, Inc. net profit margin is -638.9%, operating margin is -682.7%, and gross margin is +82.9%. Below-average margins reflect competitive or cost pressures. Return on Equity is -45.7%.
Is VIR growing earnings?
Yes, VIR earnings are accelerating — EPS growth of +17.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-443M. Earnings momentum is strengthening.
What was VIR's best earnings year?
Vir Biotechnology, Inc.'s highest annual net income on record is $529M, achieved in fiscal year 2021. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.
What were VIR's earnings last quarter?
VIR's most recent reported quarter was Q1 2026. Net income was $-126M with diluted EPS of $-0.85. For a full breakdown of all quarters, see the quarterly earnings table on this page.